Allison Thurman

Statistics

Publications

Citations

580

H-Index

Active since

1994

Affiliations

The University of Texas at San Antonio Health Science Center(Current)

International Drug Development

Allison Thurman is an author at The University of Texas at San Antonio Health Science Center specializing in pharmacology, toxicity management, and cancer pharmacology.

Publications per year

1994–1999

Publications

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

Mace L. Rothenberg, John R. Eckardt, John G. Kuhn et al. · Journal of Clinical Oncology · 1996 · 352 citations

Medicine, Oncology, Pharmacology +13

A Bioavailability and Pharmacokinetic Study of Oral and Intravenous Hydroxyurea

Gladys Rodriguez, John G. Kuhn, Geoffrey R. Weiss et al. · Blood · 1998 · 83 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors

S. Gail Eckhardt, Jinee Rizzo, Kevin Sweeney et al. · Journal of Clinical Oncology · 1999 · 71 citations

Medicine, Oncology, Pharmacology +17

A Phase II Trial of DaunoXome, Liposome- Encapsulated Daunorubicin, in Patients with Metastatic Adenocarcinoma of the Colon

John R. Eckardt, Elizabeth Campbell, H. A. Bums et al. · American Journal of Clinical Oncology · 1994 · 38 citations

Medicine, Oncology, Pharmacology +17

Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.

S. Gail Eckhardt, Sharyn D. Baker, John R. Eckardt et al. · PubMed · 1998 · 36 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

1–5 of 5